Finally, different melanoma cell lines with acquired resistance to vemurafenib and dabrafenib were described to modulate the expression of various NK cell ligands (e.g., MICA/B and HLA-ABC), resulting in higher sensitivity to NK cell lysis compared to the parental cell lines, suggesting patients gaining such resistance might benefit from strategies to enhance NK cell activity [197,198]. This evidence concerns the gene MICA and melanoma.